Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1

Status

Recruiting 3Completed 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 22Lung Neoplasms 17Cholangiocarcinoma 13Biliary Tract Neoplasms 13Small Cell Lung Carcinoma 12Triple Negative Breast Neoplasms 8Breast Neoplasms 8Neoplasms 6Neoplasm Metastasis 5Liver Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Pancreatic Neoplasms 4Carcinoma 4Non-Muscle Invasive Bladder Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Adenocarcinoma Of Esophagus 3Pathologic Complete Response 2Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Bile Duct Neoplasms 2Advanced Biliary Tract Cancer 2Adenocarcinoma of Lung 2Adenocarcinoma 2Vaccinia 1SCLC, Limited Stage 1Resectable Intrahepatic Cholangiocarcinoma 1

Interventions

Gemcitabine 7Oxaliplatin 6Cisplatin 5durvalumab 3130-nm albumin-bound paclitaxel 3pembrolizumab 2Leucovorin 2Drug Therapy 2zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1sintilimab 1pertuzumab 1anlotinib 1Trastuzumab 1Taxes 1Standard of Care 1Platinum 1Observation 1Nivolumab 1Neoadjuvant Therapy 1Long-Term Synaptic Depression 1Irinotecan 1Folfox protocol 1Fluorouracil 1Everolimus 1Commerce 1Cholangiopancreatography, Endoscopic Retrograde 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Gallbladder Neoplasms × durvalumab × Clear all
NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07221253 2026-03-17

AB02

AstraZeneca

Phase 3 Recruiting
1,100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT06214572 2025-04-11

RUGB

Tata Memorial Centre

Phase 2/3 Recruiting
249 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡